<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636191</url>
  </required_header>
  <id_info>
    <org_study_id>HND-IM-030</org_study_id>
    <nct_id>NCT03636191</nct_id>
  </id_info>
  <brief_title>The Effect of a Probiotic on Upper Respiratory Tract Infections</brief_title>
  <acronym>PIP-U</acronym>
  <official_title>The Effect of Lactobacillus Rhamnosus (LGG®) on the Defence Against Pathogens in the Upper Respiratory Tract in Healthy Children - a Single-center, Randomized, Double-blind, Placebo-controlled Study With 16 Weeks Intervention.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chr Hansen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Onorach Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CPS Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chr Hansen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, two-armed, parallel-group study
      in healthy children aged 2-6 years. The study will investigate the effect of daily intake of
      a probiotic on Upper Respiratory Tract Infections (URTI) during a 16-week intervention.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of URTI</measure>
    <time_frame>16 weeks</time_frame>
    <description>The incidence of URTI measured as the number of URTI episodes diagnosed by a GP according to the prespecified, well-defined criteria, adjusted for sample size.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of URTI with pathogens</measure>
    <time_frame>16 weeks</time_frame>
    <description>The incidence of URTI measured as the number of URTI episodes diagnosed by a GP according to the prespecified, well-defined criteria, for which a pathogen is identified in nasal swabs, adjusted for sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of days with URTI symptoms</measure>
    <time_frame>16 weeks</time_frame>
    <description>The number of days with URTI symptoms for URTIs that were diagnosed by a GP, adjusted for sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days with temperature ≥ 38 °C</measure>
    <time_frame>16 weeks</time_frame>
    <description>The number of days with temperature ≥ 38 °C during an URTI episode, which was diagnosed by a GP, adjusted for sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WURSS-K score</measure>
    <time_frame>16 weeks</time_frame>
    <description>The Area under Curve for daily Wisconsin Upper Respiratory Symptom Survey for Kids (WURSS-K) score (range: not sick - very sick) during an URTI episode, which was diagnosed by a GP, adjusted for sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with one or more episode of URTI</measure>
    <time_frame>16 weeks</time_frame>
    <description>The number of subjects with one or more episode of URTI, which was diagnosed by a GP, adjusted for sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days of absence from daycare or primary school</measure>
    <time_frame>16 weeks</time_frame>
    <description>The number of days of absence from daycare or primary school during an URTI, which was diagnosed by a GP, adjusted for sample size.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">619</enrollment>
  <condition>Infections, Upper Respiratory Tract</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic strain</intervention_name>
    <description>Lactobacillus</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children aged 2-6 years, both inclusive, at the time of informed consent

          2. No URTI at the time of inclusion as assessed by a GP

          3. Attending day-care with at least 10 children or primary school with at least 10
             children in the class for at least 20 hours a week

          4. Generally healthy as determined by a GP

          5. Guardian consents to participate in the study and to comply with all its procedures

        Exclusion Criteria:

          1. Any known concomitant chronic infections, chronic systemic diseases, autoimmune
             diseases (e.g. asthma), immunodeficiency, metabolic diseases, chronic respiratory
             tract diseases including respiratory allergies and cystic fibrosis, congenital cardiac
             defects.

          2. Suspected or challenge-proved food allergy

          3. Use of any prescribed immune suppressive medications at enrolment

          4. Use of oral or IV antibiotics in the 1 month before randomisation

          5. Not willing to exclude pre/pro/synbiotics during the study

          6. Intake of Echinacea, high dose vitamins or Zinc four weeks before and during the study
             period.

          7. Language limitations regarding interviews or questionnaires

          8. Participation in other clinical studies in the last 2 months

          9. Planning extensive travel (for &gt;1 month) during the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Crawford, DRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>CPS Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CPS Research</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

